Carregant...
Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
Everolimus (RAD001) is an inhibitor of mammalian target of rapamycin used in combination with exemestane to treat hormone receptor-positive advanced breast cancer. However, not all patients are equally sensitive to RAD001 and certain patients develop resistance. Therefore, the present study analyzed...
Guardat en:
| Publicat a: | Oncol Lett |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5587981/ https://ncbi.nlm.nih.gov/pubmed/28927154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6597 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|